New hope for Hard-to-Treat cancers: experimental drug targets KRAS G12D mutation
NCT ID NCT06797336
First seen Jan 05, 2026 · Last updated May 24, 2026 · Updated 23 times
Summary
This early-phase study tests an experimental drug called PT0253 in adults with advanced solid tumors that have a specific genetic change (KRAS G12D mutation). The main goals are to check the drug's safety, find the best dose, and see how the body processes it. About 115 participants will receive the drug by mouth, and researchers will monitor side effects and tumor response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Dana Farber/Massachusetts General Hospital, Inc
RECRUITINGBoston, Massachusetts, 02215, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
NEXT Virginia
RECRUITINGFairfax, Virginia, 22031, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
New Experimental Therapeutics of San Antonio LLC
RECRUITINGSan Antonio, Texas, 78229, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
SCRI Lake Mary
RECRUITINGNashville, Tennessee, 37203, United States
Contact
-
SCRI Oncology Partners
RECRUITINGNashville, Tennessee, 37203, United States
Contact
-
START - South Texas Accelerated Research Therapeutics, LLC
RECRUITINGSan Antonio, Texas, 78229, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
START Mountain Region
RECRUITINGWest Valley City, Utah, 84119, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.